Pathophysiology of Tumor Neovascularization by Furuya, Mitsuko et al.
Vascular Health and Risk Management 2005:1(4) 277–290
© 2005 Dove Medical Press Limited. All rights reserved
277
REVIEW
Abstract: Neovascularization is essential to the process of development and differentiation of
tissues in the vertebrate embryo, and is also involved in a wide variety of physiological and
pathological conditions in adults, including wound repair, metabolic diseases, inflammation, cardio-
vascular disorders, and tumor progression. Thanks to cumulative studies on vasculature, new
therapeutic approaches have been opened for us to some life-threatening diseases by controlling
angiogenesis in the affected organs. In cancer therapy, for example, modulation of factors
responsible for tumor angiogenesis may be beneficial in inhibiting of tumor progression. Several
antiangiogenic approaches are currently under preclinical trial. However, the mechanisms of
neovascularization in tumors are complicated and each tumor shows unique features in its
vasculature, depending on tissue specificity, angiogenic micromilieu, grades and stages, host
immunity, and so on. For better understanding and effective therapeutic approaches, it is important
to clarify both the general mechanism of angiogenic events and the disease-specific mechanism
of neovascularization. This review discusses the general features of angiogenesis under physiological
and pathological conditions, mainly in tumor progression. In addition, recent topics such as
contribution of the endothelial progenitor cells, tumor vasculogenic mimicry, markers for tumor-
derived endothelial cells and pericytes, and angiogenic/angiostatic chemokines are summarized.
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Introduction
The vascular system is a functional organ that starts developing in the very early
stage of embryogenesis (Sumpio et al 2002). Hemangioblasts, the progenitor cells
derived from embryonic mesoderm, generate the blood-island composed of
endothelial progenitor cells (also named angioblasts) and hematopoietic stem cells.
This process of primary vascular plexus formation is called “vasculogenesis” (Risau
1997). During development and differentiation, vasculature is further differentiated
by sprouting, intussusception, and bridging of endothelial cells from the preexisting
plexus, and both cellular and structural maturation proceed. This step is called
“angiogenesis” (Figure 1) (Carmeliet and Collen 1999). In embryogenesis, dynamics
of neovascularization are finely controlled by numerous angiogenic and angiostatic
factors (Distler et al 2003). In the postnatal stage, the constituent cells of blood vessels
are generally quiescent in G0 phase of cell cycle, which means in a mature and
differentiated state, whereas in certain organs/tissues such as ovary, endometrium,
and placenta, vascular remodeling takes place actively under physiological controls
(Shweiki et al 1993; Ferrara et al 1998).
Apart from the physiological angiogenesis, pathological angiogenesis occurs under
specific conditions such as wound repair, diabetic retinopathy, rheumatoid arthritis,
and tumors (Dvorak et al 1999). Such pathological angiogenesis plays an important
role in the process of progression and/or healing of each disease (Carmeliet 2003).
Newly formed vessels in adult tissues are generally thought to be derived from the
neighboring cells of preexisting blood vessels (Hanahan and Folkman 1996). In
addition, recent studies on progenitor cells have revealed another mechanism of
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neovascularization, ie, contribution of bone marrow-derived
and circulating endothelial precursor cells to adult
vasculogenesis/angiogenesis, which will be discussed later.
The present review focuses on features of neo-
vascularization under physiological and pathological
conditions, with an emphasis on tumor neovascularization.
Constituent cells of blood vessels
Constituent cells of blood vessels, endothelial cells (EC),
pericytes, and vascular smooth muscle cells (VSMC) are
differentiated from separate types of precursor cells, or from
common vascular progenitor cells (Carmeliet 2000;
Yamashita et al 2000). VSMC of great vessels are also
derived from neural crest cells (Gittenberger-de Groot et al
1999). Furthermore, EC and endothelial precursor cells have
been shown to transdifferentiate into pericytes or other
mesenchymal cells under specific conditions (Paranya et al
2001; Badorff et al 2003).
Since EC form the inner lining of blood vessels and are
directly exposed to blood flow, they stand as a primary gate
for intravasation and extravasation of blood cells, plasma
proteins, and various biochemical substances (Mitchell and
Contran 1999). Blood vessels themselves may also
synthesize and secrete bioactive substances (Cotran et al
1999). Vascular cells participate in blood pressure control,
immune responses, and many other homeostatic regulations
(Schoen and Cotran 1999). There are various receptors
expressed on the surface of EC, and many kinds of
intercellular junctional molecules mediate between EC–EC
and EC–pericytes/VSMC interaction (Cleaver and Melton
2003). In response to cytokines, chemokines, and other
vasoactive substances, these receptors and junctional
molecules mediate several signalings that alter vascular tone
and permeability, and/or cause neointimal formation through
proliferation and migration of both EC and pericytes/VSMC
(Dvorak et al 1999).
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Figure 1 Vasculogenesis and angiogenesis during development and differentiation. The mesodermal progenitor cells derived from embryonic stem cells (ESC)
differentiate into various vascular and hematopoietic cells. Vascular progenitor cells (VPC) are bi-potentials that can differentiate into either pericyte/vascular smooth
muscle cells (VSMC) or endothelial cells (EC) lineage. Hemangioblasts generate the blood island composed of endothelial progenitor cells, also called angioblasts
(EPC) and hematopoietic stem cells (HSC). EPC differentiate into EC and form vessel tubes, whereas HSC further differentiate into lymphoid/myeloid lineage.
Nascent vessels are stabilized by vascular mural cell coverage and extracellular matrix.Vascular Health and Risk Management 2005:1(4) 279
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Molecules that regulate
angiogenesis
Multiple steps are required for angiogenesis in adult tissues.
At the onset of angiogenic sprouting, proangiogenic factors
including vascular endothelial growth factor (VEGF) and
related molecules act on EC and increase EC permeability.
In response to the angiogenic switch, pericytes and VSMC
are detached from the preexisting vessels (Carmeliet and
Collen 1999; Dvorak et al 1999). In this process, degradation
of the basement membrane and extracellular matrix (ECM)
by proteolytic enzymes is required. Matrix metallo-
proteinases (MMPs), tissue inhibitors of MMPs (TIMPs),
elastases, and cathepsins play important roles for matrix
remodeling (Kalluri 2003). Activated EC then migrate into
the perivascular space and proliferate to form tubular
structures. In succession, pericytes/VSMC envelope these
EC and thus nascent vessels are stabilized (Carmeliet 2000).
Representative growth factors and cytokines that control
angiogenesis include VEGF, fibroblast growth factors
(FGF), angiopoietins (Ang), transforming growth factor-β
(TGF-β), and tumor necrosis factor-α (TNF-α). VEGF acts
rather more selectively on EC than other cytokines do (eg,
FGF, TGF-β, and TNF-α) and works as a master switch of
angiogenesis in an early stage of both physiological and
pathological conditions (Dvorak 2002). In addition to the
factors listed above, there are numerous important factors
that control vessel remodeling. Among them, two key
molecules, VEGF and FGF, are highlighted in this review.
Vascular endothelial growth factor
Members of the VEGF family are VEGF-A, -B, -C, -D, -E,
and placenta growth factor (PlGF). VEGF-A gene is
alternatively spliced to form several isoforms such as VEGF-
A121,VEGF-A165, and VEGF-A189 in humans (Dvorak 2002;
Ruhrberg 2003). These isoforms differ in the presence or
absence of two heparin-binding domains of VEGF-A.
VEGF-A165 is considered to be the most predominant
isoform that supports angiogenic growth. Studies on VEGF
isoforms have shown the importance of different isoforms
for vessel specification. For example, mice selectively
expressing a single
 isoform VEGF-A164 (VEGF
164/164) were
healthy and had normal
 retinal angiogenesis, whereas
 mice
which expressed VEGF
188/188 selectively displayed normal
venular outgrowth, but had impaired
 arterial development
(Stalmans et al 2002). Mice that expressed VEGF
120/120
showed impaired vessel outgrowth (Ng et al 2001; Stalmans
et al 2002).
VEGF-A functions as a main ligand for receptors
VEGFR-1 (fms-like tyrosine kinase-1 [Flt-1]), VEGFR-2
(fetal liver kinase-1 [Flk-1]/kinase insert domain protein
receptor [KDR]) and neuropilin-1/-2 (NRP-1/-2) (Dvorak
2002). Angiogenic VEGF signaling is mediated mainly
through VEGFR-1 and VEGFR-2: members of receptor
tyrosine kinases (RTKs) that contain the cytoplasmic
tyrosine kinase domain separated by an intervening,
noncatalytic, circa 70 amino acid sequence (Podar and
Anderson 2005). This structure is common among the
related family members, such as platelet-derived growth
factor receptor (PDGFR), c-Kit, and c-Fms (Sherr 1990).
The binding ability of VEGF-A to VEGFR-1 is at least
10-fold stronger than that to VEGFR-2 (Shibuya 2001). In
contrast, the kinase activity of VEGFR-2 is 10-fold higher
than that of VEGFR-1. Furthermore, VEGFR-1 tyrosine
kinase-deficient homozygous mice developed normal
vessels and survived, whereas VEGFR-2
–/– mice embryos
died from a failure of blood island formation and
vasculogenesis (Shalaby et al 1995; Hiratsuka et al 1998).
Thus, VEGF signaling in angiogenesis may be mediated
mainly by VEGFR-2. The role of VEGFR-1 seems to be
more complex. A soluble form of VEGFR-1 suppressed EC
proliferation (Kendall and Thomas 1993). VEGFR-1–/– mice
died in utero with an overgrowth of EC-like abnormal cells
(Fong et al 1995). These findings indicate that VEGFR-1
may negatively regulate angiogenesis (Fong et al 1999;
Kearney et al 2002). On the other hand, VEGFR-1 was
shown to contribute to vascular sprouting (Kearney et al
2004) and metastasis (Hiratsuka et al 2002). Therefore, the
pathophysiological roles of VEGFR-1 may depend on the
local milieu and the stage of angiogenesis. Studies on
hematopoietic stem cells have elucidated another role of
VEGFR-1 in the repopulation of bone marrow-resident
progenitor cells, which will be discussed later. VEGFR-1
also serves as a receptor for PlGF and VEGF-B (Sawano et
al 1996; Olofsson et al 1998). VEGF-C and -D interact with
VEGFR-3 (fms-like tyrosine kinase-4 [Flt-4]) expressed
mainly in lymphatic EC, and they seem to have a major role
in lymphangiogenesis and tumor metastasis via lymphatic
vessels (Jeltsch et al 1997). VEGF-C and -D also potentially
bind to VEGFR-2 (Joukov et al 1996).
Fibroblast growth factors
The FGF family is composed of over 20 members and its
effects are mediated by four RTKs, ie, FGF receptor-1
(FGFR-1), -2, -3, and -4. FGF are required for development
and differentiation of various organs from the early stage ofVascular Health and Risk Management 2005:1(4) 280
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embryogenesis, as indicated by the fact that the mice
deprived of either FGFR-1 or FGFR-2 die prior to
gastrulation (Deng et al 1994; Xu et al 1998). In the context
of angiogenesis, overexpression of FGF-2 (also named basic
FGF [bFGF]) is known to increase angiogenic activity by
inducing chemotaxis and migration of EC, through FGFR-1-
mediated signaling (Tanghetti et al 2002). FGF-2 has also
been shown to collaborate with other angiogenic molecules
such as VEGF, plasminogen activator and hepatocyte growth
factor (HGF) (Bikfalvi et al 1997; Onimaru et al 2002).
FGF-2 may efficiently integrate angiogenic activities of several
factors in a synergetic manner (Ribatti and Presta 2002).
With regard to antiapoptotic mechanism in EC, FGF-2
preferentially protects EC from intrinsic stress-mediated
apoptosis such as serum starvation, whereas VEGF works
against the extrinsic apoptotic pathways induced by death
ligands such as TNF-α and Interferon-γ (IFN-γ) (Alavi et al
2003). Since both FGF-2 and VEGF are known to be
produced abundantly in various angiogenic diseases,
targeting both factors would be expected to result in better
antiangiogenic effects.
Cross-talk between endothelial
cells and pericytes/extracellular
matrix
There are some angiogenic factors that control cross-talk
among different types of cells in the vasculature. For
example, tyrosine kinase with Ig and EGF homology
domain-2 (Tie-2) is expressed in EC, whereas angiopoietin-1
(Ang-1), the ligand for Tie-2, is produced by pericytes, and
they cooperatively work for vascular stabilization (Davis et
al 1996; Suri et al 1996). On the other hand, Ang-2 is
produced by activated EC and competitively inhibits the
function of Ang-1 (Tanaka et al 1999). As another example,
platelet-derived growth factor-B (PDGF-B) expressed in EC
has essential roles in stabilization of nascent vessels by
recruiting pericytes in which the receptor for PDGF-B
(PDGFR-β) is expressed (Lindahl et al 1998; Hellstrom et
al 2001). Studies using knockout mice deprived of the factors
such as those mentioned above have shown that pro-
angiogenic signalings in EC and regulatory systems in which
pericytes/VSMC participate are indispensable for embryonic
vascular development and maturation (Soriano 1994; Sato
et al 1995; Ferrara et al 1996; Hellstrom et al 2001).
Signalings in vascular cells are also controlled by ECM
and luminal blood flow (eg, shear stress and hemodynamic
load) as well as by humoral factors (Li et al 1999; Kalluri
2003). Mechanical force is known to act on several sensors
including PDGFR-β, integrins and ion channels in the
vascular cells, and to modulate cellular morphology (Li and
Xu 2000). Certain integrin members are specifically
expressed in vasculature and interact with the corresponding
ligands on ECM (Hodivala-Dilke et al 2003). Such integrin-
matrix interaction mediates secretion and activation of
proteolytic enzymes and contributes to matrix remodeling.
Integrins αVβ3 and αVβ5, in particular, have been well
characterized (Eliceiri and Cheresh 2001). These integrins
are generally upregulated in angiogenic vessels, and are
regarded to possess proangiogenic function (Brooks et al
1994; Dallabrida et al 2000; Camenisch et al 2002).
However, studies using mice lacking β3 and β5 subunits
revealed that integrins αVβ3 and αVβ5 are dispensable for
embryonic vascular development (Reynolds et al 2002;
Reynolds et al 2004). It is more likely that the real function
of these integrins is more complex than first thought.
Some endogenous angiogenesis inhibitors, eg, tumstatin,
endostatin, and canstatin, bind certain integrins on EC
(Kalluri 2003). Tumstatin is known to induce EC-specific
apoptosis in which the presence of integrin αVβ3 is
necessary as the binding site for this molecule (Maeshima
et al 2002). Currently, a monoclonal antibody against
integrin αVβ3 (Vitaxin) is under preclinical investigation
for antiangiogenic therapies against rheumatoid arthritis and
malignant tumors. Further studies are required to clarify
the effectiveness of such therapeutic approaches and in
relation to the function of endogenous angiogenic inhibitors.
Tissue specificity in normal
vasculature
Every tissue carries a tissue-specific signature in its
vasculature (Ruoslahti and Rajotte 2000). Permeability of
capillaries varies among organs. For example, liver
sinusoidal EC are discontinuously lined without support of
the basement membrane and have innumerable fenestrations.
Liver sinusoidal EC express very low or undetectable levels
of E-selectin, P-selectin, and CD31 (also named platelet
endothelial adhesion molecule-1 [PECAM-1]), and they lack
Factor VIII and Weibel-Palade bodies, sites of storage of
von Willebrand factor (Lalor et al 2002). On the other hand,
cerebral capillaries are particularly impermeable, and the
system of tight barrier between microcirculation and brain
parenchyma is named blood-brain barrier (BBB). EC in this
vasculature lack fenestration and are connected to each other
by adherence and tight junctions. Tight junctional moleculesVascular Health and Risk Management 2005:1(4) 281
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such as junctional adhesion molecule-1 (JAM-1), occludin,
and claudins are well developed in cerebral EC, and they
contribute to precise regulation of paracellular diffusion and
ion flux (Hirase et al 1997; Morita et al 1999; Aurrand-
Lions et al 2001; Brown and Davis 2002).
Recent development of genomics and proteomics has
enabled us to address organ-specific EC markers, eg, lung-
specific endothelial cell adhesion molecule (Lu-ECAM-1),
dipeptidyl peptidase IV (DPP IV), and aminopeptidase-P
in rodent lung EC (Zhu et al 1991; Johnson et al 1993; Oh
et al 2004). Making use of such tissue-specific vessel
markers may be of great advantage in efficient
 drug/gene
delivery to the targeted organ (Arap et al 2002). However,
if other unknown sites share these markers, such drug/gene
delivery might induce accumulation of therapeutic
substances in unexpected sites. Therefore, the application
of tissue-specific EC markers for therapeutic strategies
should be carefully considered.
Special features of tumor vessels
A landmark publication on tumor pathophysiology,
Hallmarks of cancer by Hanahan and Weinberg (2000),
defined seven critical features of cancer phenotype. One of
the listed hallmarks, “sustained angiogenesis”, is explained
as an acquired event during tumor development via an
angiogenic switch from vascular quiescence. It is now well
recognized that tumor vasculature is different from normal
vasculature in the context of architecture and biological
behavior. Progressive tumor tissues easily become hypoxic
and necrotic because of rapid proliferation and insufficient
blood supply (Pugh and Ratcliffe 2003). Host immune cells
may infiltrate into the lesion, although the immune response
generally fails to eradicate the tumors (Janeway et al 2001).
Under such proinflammatory microenvironments, tumor
angiogenic vessels show abnormal maturation. The
conventional structure of peripheral blood vessels composed
of arterioles, capillaries, and venules is abrogated. Instead,
irregular sprouting and branching of angiogenic vessels with
disordered coverage of pericytes are demonstrated in
morphology (McDonald and Choyke 2003). Tumor
vasculature frequently shows elevated permeability,
increased proteolytic activities, and hemorrhage (Dvorak
2002; Hodivala-Dilke et al 2003).
Therapeutic approaches using antiangiogenic agents are
currently clinically approved in some advanced cancers, and
the possibilities for successful antiangiogenic therapies will
be further opened to various angiogenic tumors (Sivakumar
et al 2004). Tumor vessels are generally derived from
preexisting resident vascular cells or recruited precursor EC
(Hanahan and Folkman 1996; Ribatti 2004). Therefore,
tumor vasculature is considered to be susceptible to
therapeutic drugs, although tumor cells often circumvent
chemotherapies and radiation (Blagosklonny 2004). It is
expected that vascular targeting molecules in tumor therapies
can be administered repetitively without inducing resistance
and that such therapy keeps cancers in the state of dormancy,
even though complete eradication may not be achieved
(Boehm et al 1997). On the other hand, recent studies have
demonstrated cytogenetic complexity of tumor vasculature;
ie, EC aneuploidy (Hida et al 2004) and “tumor vasculogenic
mimicry”, as discussed later (Maniotis et al 1999). In relation
to possible resistance against antiangiogenic therapies,
detailed studies on special features of tumor vessels,
including chromosomal instability of tumor, will be required.
Tumor-derived endothelial cells
Tumor-derived endothelial cells (TEC) have been
characterized intensively using highly reliable methods, such
as endothelial purification from tumor tissues (St Croix et
al 2000; Bussolati et al 2003) and immunoelectron
microscopy (Sincock et al 1999). Comparison of molecular
profiles of normal EC and TEC, by microarray analysis and
proteomic mapping, has shown upregulation of various
angiogenesis-related molecules (Shih et al 2002; Mutuberria
et al 2004; Oh et al 2004). These molecules, highly expressed
in TEC, although not specific in TEC, may be involved in
increased permeability, proliferation, migration, and
antiapoptosis of TEC, and also in matrix remodeling in
tumor progression (St Croix et al 2000; Bussolati et al 2003).
Currently, several molecules such as VEGFR-2, CD105 (also
named endoglin), endothelial protein-disulfide isomerase
(EndoPDI), and tumor endothelial markers (TEMs) are
noted as representative surface markers of TEC because they
are rarely expressed in the corresponding normal EC
(Carson-Walter et al 2001; Duff et al 2003; Sullivan et al
2003; Fonsatti and Maio 2004). Under other conditions,
including embryogenesis and inflammatory diseases, these
markers may also be upregulated in nontumor EC (Gougos
et al 1992; Carson-Walter et al 2001).
Clinical application of antiangiogenic therapy has some
targets: membrane proteins that are specifically expressed
in TEC (eg, VEGFR, CD105); intracellular signaling molecules
that are highly activated in TEC (eg, mitogen-activated
protein kinase [MAPK], Akt); and proangiogenic factorsVascular Health and Risk Management 2005:1(4) 282
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produced by tumor cells (eg, VEGF, FGF). When TEC
markers are used for targeting, these markers should be
localized specifically in TEC of the lesion but not expressed
in normal EC of the other organs/tissues. For example, a
recent study revealed that annexin A1 was highly expressed
in TEC of rat lung tumors (Oh et al 2004), and neither in
the corresponding normal lung nor in the other organs, which
satisfied the requirement for therapeutic application in both
organ specificity and TEC specificity. In the latter study, in
comparison with annexin A1, other molecules were also
found to be highly expressed in TEC; those such as
VEGFR-1, VEGFR-2, NRP-1, and CD105 were detectable
in heart, kidney, and liver. Detailed studies on TEC-specific
molecules in each tumor will provide us with more effective
antiangiogenic therapies.
Signal transduction in tumor-
derived endothelial cells
The majority of TEC-specific molecules highlighted so far
are present on the cell surface. In addition to these
transmembrane molecules, cells in tumor vasculature also
utilize various intracellular signaling cascades and
transcription factors to sustain angiogenesis (Sato 2000;
Shibuya 2003). Some key angiogenic factors stimulate RTKs
such as VEGFR, Tie, and FGFR, and it is expected that these
RTKs-mediated signalings are activated in angiogenic EC
in vivo (Pintus et al 2002; Shu et al 2002; Deregibus et al
2003; Yilmaz et al 2003). The representative intracellular
molecules involved in RTKs-mediated signaling pathways
include: (1) Src homology and collagen (Shc) that binds to
growth factor receptor bound protein 2 (Grb2)/son of
sevenless (SOS) and consequently activates Ras/rapid
fibrosarcoma virus (Raf)/MAPK pathways; (2) phos-
phoinositide-specific phospholipase C-γ (PLC-γ) that
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to
generate inositol 1,4,5-triphosphate (IP3) and diacylglycerol
(DAG) which activates protein kinase C (PKC); and (3)
phosphatidylinositol 3-kinase (PI3K) that leads to activation
of Akt (Hubbard et al 1998; Shibuya 2003). Signaling
pathways through (1) and (2) induce increased permeability,
proliferation, and migration of EC, and that, through (3),
controls survival signals (Datta et al 1999; Pearson et al
2001). Limited information is currently available on the
signaling processes that occur in TEC because many of the
studies were carried out using non-TEC EC such as human
umbilical vein endothelial cells (HUVEC), other primary
cultured EC, or immortalized EC. TEC might preferentially
take advantage of special signaling molecules under tumor
microenvironment in vivo to sustain the aberrant angio-
genesis, and to escape from apoptosis and host immunity
(Wang et al 2002; Bussolati et al 2003). In the studies using
TEC isolated from human tumors, PI3K/Akt was shown to
be upregulated in renal cell carcinomas (Bussolati et al
2003), and colon carcinoma-derived TEC under hypoxia
condition showed resistance to the antiangiogenic effects
of IFN-γ by upregulating B cell lymphoma/leukemia-2
(Bcl-2) (Wang et al 2002). Further studies using TEC are
necessary to clarify the detailed mechanisms of signalings
and transcriptional regulation.
Contribution of endothelial
progenitor cells, hematopoietic
stem cells, and cells of the
monocytic lineage to
neovascularization
Recent studies have demonstrated the participation of
endothelial progenitor cells (EPC), hematopoietic stem cells
(HSC), and myeloid precursors in various pathological
angiogenesis including tumor vasculature. EPC can be
detected by the progenitor cell markers such as CD34 and
AC133 (also named CD133) in addition to general EC
markers (Ribatti 2004). Normally in adults, EPC are
localized both in the bone marrow and in circulation
(Asahara et al 1997; Patterson 2003). Although the number
of circulating EPC is very small under normal conditions,
they can be mobilized from the bone marrow and proliferate
by hypoxic stimuli and VEGF upsurge (Aicher et al 2003;
Rafii and Lyden 2003; Tepper et al 2005). Pathological
neovascularization is now believed to occur not only from
preexisting vasculature but also by the recruitment of
circulating and bone marrow-mobilized EPC (Figure 2).
Studies on the existence of EPC in the angiogenic vessels
showed considerably varying results (Murayama et al 2002;
Vajkoczy et al 2003). Contribution of EPC to tumor
neovascularization may depend, at least in part, on
aggressiveness of the tumor (Li et al 2004).
In embryonic vasculogenesis, hemangioblasts are
differentiated into EPC and HSC, and the latter is further
subdivided into lymphoid and myeloid lineage (Figure 1).
Detailed studies have revealed that HSC and myelo-
monocytic population are involved in adult vascular
remodeling under pathological conditions such as
myocardial infarction and liver regeneration (Wang et alVascular Health and Risk Management 2005:1(4) 283
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2003; Nygren et al 2004). Studies on tumor vasculature
using Id-deficient mice revealed that bone marrow-derived
VEGFR-1
+ HSC, expressing both myeloid specific markers
and EC markers, cooperated with VEGFR-2
+ EPC and
contributed to the development of tumor vasculature (Lyden
et al 2001; Hattori et al 2002). It remains controversial as to
whether HSC participate in angiogenesis and tissue
regeneration by transdifferentiation or by cell fusion (Wagers
et al 2002; Vassilopoulos et al 2003; Wang et al 2003). A
very recent study, in patients who developed cancers after
bone marrow transplantation from the opposite sex,
supported the notion that HSC potentially produce EC,
though transplanted HSC contributed to only 4.9% of the
total TEC (Peters et al 2005). In the latter study, bone
marrow-derived TEC were shown to have the diploid copy
number of transplanted sex chromosome, indicating that cell
fusion may not be the case (Peters et al 2005).
VEGFR-1
+ HSC cells are known to possess myelo-
monocytic markers. Studies on peripheral blood monocytes
revealed that further differentiated hematopoietic cells also
contribute to neovascularization. Monocytes, macrophages,
and dendritic cells (DC) in the peripheral blood that do not
have a significant proliferative capacity (ie, the hallmark of
progenitor cells) undergo EC-like specialization in certain
pathological conditions (Rehman et al 2003; Zhao et al 2003;
Conejo-Garcia et al 2004). Differentiation status of these
myelomonocytic cells and their contribution to neo-
vascularization may vary among diseases (Rehman et al
2003; Zhao et al 2003). In tumor vasculature in vivo,
heterogeneity of EC may depend on both biological
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Figure 2 Pathological neovascularization during tumor progression. Tumor tissue secretes various proinflammatory factors and vasoactive substances that sustain
neovascularization. Tumor vasculature is supported not only by angiogenesis derived from preexisting vasculature, but also by vasculogenic mimicry and
neovascularization from progenitor cells/monocytes. Endothelial progenitor cells (EPC) from the bone marrow and in circulation, hematopoietic stem cells (HSC), and
further differentiated cells of the monocytic lineage such as macrophages and dendritic cells potentially contribute to pathological neovascularization; although the
percentage of progenitor cells is generally low.
Abbreviations: EC, endothelial cells; EPC, endothelial progenitor cells; HSC, hematopoietic stem cells; VEGF, vascular endothelial growth factor; VEGFR-1+, fms-like
tyrosine kinase-1; VEGFR-2+, fetal liver kinase-1/kinase insert domain protein receptor; VSMC, vascular smooth muscle cells.Vascular Health and Risk Management 2005:1(4) 284
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properties of tumor cells and host tissue environments
(Conejo-Garcia et al 2004; Coukos et al 2005). Further
investigation is required to clarify the contribution of these
EC precursor cells in angiogenic diseases.
Tumor vasculogenic mimicry
Studies on the specific features of tumor progression have
revealed another blood passage: fluid-conducting ECM
meshwork lined by tumor cells instead of EC (Hendrix et al
2003). In several types of tumors, such as aggressive
melanoma, ovarian, prostatic, and breast carcinomas, tumor
cells themselves may sometimes display endothelial cell-
like characteristics (Shirakawa et al 2001; Sood et al 2001;
Hendrix et al 2002; Sharma et al 2002) known as “tumor
vasculogenic mimicry” (Maniotis et al 1999). This
alternative vascular network is composed of tumor cells that
express some endothelial markers and embryonic
vasculogenesis-related molecules
 such as VE-cadherin,
CD34, and CD105 (Seftor et al 2002; Hendrix et al 2003).
A similar process of vascular remodeling has been reported
in physiological conditions. For example, during placenta
formation, cytotrophoblasts establish blood pathways by
invading uterine myometrium (Lyall et al 2001). In this
process, some cytotrophoblasts were shown to undergo
epithelial to EC transformation and replace EC lining of
spiral arteries of maternal origin (Zhou et al 1997), and this
has been referred to as “pseudo-vasculogenesis” (Damsky
and Fisher 1998).
The detailed mechanism of tumor vasculogenic mimicry
remains to be further elucidated, including responsible
transcription factor(s) that alter tumor cell plasticity. At
present it is considered that, under special micro-
environments, tumor cells may dedifferentiate into a
pluripotent, embryonic-like phenotype, or may trans-
differentiate into EC-like phenotype during development
(Hendrix et al 2003).
Tumor vasculogenic mimicry was reported to be resistant
to angiogenesis inhibitors such as endostatin and TNP-470
in vitro (van der Schaft et al 2004). The biological properties
of this special vasculature are also the subject of further
studies; in particular, on whether and how this vascular
network shows altered responsiveness or resistance to
antiangiogenic drugs.
Pericytes and vascular smooth
muscle cells
During embryogenesis, pericytes and VSMC are dif-
ferentiated from smooth muscle progenitor cells, common
vascular progenitor cells (VPC), and/or transdifferentiated
from EC (Carmeliet 2000; Yamashita et al 2000; Jain 2003).
These vascular mural cells are necessary for vessel
stabilization and maturation, and they cooperate with EC
for controlling vascular permeability, tone, and remodeling
(Jain 2003). Representative markers for pericytes and VSMC
include α-smooth muscle actin, desmin, and PDGFR-β
(Morikawa et al 2002). These mural cells protect EC from
apoptosis caused by VEGF-withdrawal and antivascular
immune responses (Benjamin et al 1999; Reinmuth et al
2001; Gee et al 2003). Both PDGF-B
–/– and PDGFR-β–/–
mice die perinatally and show fragile vasculature without
coverage by pericytes, indicating that PDGF is indispensable
for vessel maturation (Soriano 1994; Levéen et al 1994).
The role of VSMC and pericytes in tumor vasculature
remains less understood than those of TEC (Abramsson et
al 2003; Gerhardt and Betsholtz 2003). In tumors, it is often
seen that only a small fraction of vessels are covered by
pericytes (Gee et al 2003), and that the pericytes are
frequently altered in morphology and are loosely attached
to TEC (Morikawa et al 2002). In rodent models,
antivascular therapy resulted in selective loss of pericyte-
negative vessels, indicating that proliferative vessels that
are not covered by pericytes may be especially susceptible
to angiogenic inhibitors (Gee et al 2003). On the other hand,
there are some tumors in which vessels are predominantly
covered with pericyte. Under such conditions, cross-talk
between pericytes and EC may work in favor of tumor
progression. Indeed, perturbation of PDGF signaling by a
kinase inhibitor selective for PDGFR successfully blocked
growth of insulinoma in RIP1Tag mice by impairing pericyte
function (Bergers et al 2003).
Each part of the vessels in a tumor is in a different
angiogenic status, with various degrees of contribution of
pericytes and VSMC. This heterogeneity may depend largely
on its developmental stage or its degree of maturation. The
tumor vessels that are covered by abundant vascular mural
cells may function as stable trunks of blood supply in tumor
progression. If these stabilized vessels are more resistant to
antiangiogenic approaches than those without pericytes,
these mural cells would be particularly important as targets
for antiangiogenic tumor therapies.
Regulator of G protein signaling 5
and vascular remodeling
Studies using either PDGF-B or PDGFR-β deficient mice
embryo indicate that a regulator of G protein signaling 5
(RGS5) may be a useful marker for pericytes and VSMCVascular Health and Risk Management 2005:1(4) 285
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(Bondjers et al 2003; Cho et al 2003). RGS5, a member of
the RGS protein superfamily, serves as GTPase-activating
proteins for Ga subunits of heterotrimeric G proteins and
negatively regulates G protein-coupled receptor (GPCR)
signaling. Expressions of RGS5 have been demonstrated in
vascular mural cells; eg, brain pericytes in mouse embryos,
smooth muscle cells in the medial wall of macaque aorta,
and tumor angiogenic pericytes in RIP1Tag mice (Adams
et al 2000; Bondjers et al 2003; Cho et al 2003; Berger et al
2005), as well as in visceral smooth muscle cells in the gut
and bronchus. On the other hand, RGS5 is not expressed in
cultured smooth muscle cells. It is detectable in HUVEC;
although its expression in HUVEC is repressed during
capillary morphogenesis (Bell et al 2001). The expression
of RGS5 has also been demonstrated in EC of cerebral
capillaries in stroke-prone spontaneously hypertensive rats
and in TEC in human renal cell carcinomas (Kirsch et al
2001; Furuya et al 2004). Accumulating data indicate that
RGS5 seems to be involved in the dynamics of pathological
angiogenesis as well as play a regular role in the
physiological cardiovascular system (Seki et al 1998; Cho
et al 2003; Wieland and Mittmann 2003). Pathophysiological
roles of RGS5 in angiogenesis should be further investigated,
especially on the nature of GPCR signalings responsible
for angiogenesis in each disease.
G protein-coupled receptor-
mediated signalings in tumor
vasculature
Several GPCR ligands are crucially involved in embryonic
vascular development and/or tumor angiogenesis, eg,
angiotensin II, endothelin-1, endocrine-gland-derived
vascular endothelial growth factor (EG-VEGF), and
sphingosine-1-phosphate (LeCouter et al 2001; Zhou et al
2001; Egami et al 2003; Chae et al 2004). In addition, several
chemokines, whose signalings are also mediated by GPCRs,
are known to play important roles in angiogenesis (Arya et
al 2003; Distler et al 2003). The involvement of these GPCR
ligands have been shown in various angiogenic disorders
and tumor vasculature (Hla 2004; Romagnani et al 2004).
It should be noted that signalings of GPCRs and RTKs may
cross-communicate; eg, PDGF-B-triggered signaling
depends in part on EDG-1 receptor signaling (Hobson et al
2001; Rosenfeldt et al 2001), and various GPCRs
transactivate epidermal growth factor receptor (EGFR)
(Prenzel et al 1999). Some intracellular regulators as RGS5
might alter not only GPCR-mediated but also RTK-mediated
signalings in pathological angiogenesis in vivo (Kehrl 1998).
Chemokines in tumor angiogenesis
Some tumors have a significant background of chronic
inflammation, eg, papilloma virus infection and chronic
hepatitis (Villa 1997; Rehermann and Nascimbeni 2005).
Even if a tumor is developed de novo without any
inflammatory background, a profound leukocyte infiltration
is frequently observed (Bukowski 1999; Coussens and Werb
2002). Furthermore, many tumors produce an array of
cytokines and chemokines. Although chemokines were
initially defined as factors that control leukocyte chemotaxis
and migration at the sites of inflammation, involvement of
chemokines have been demonstrated in various diseases
other than inflammation, and it is now widely accepted that
many types of cells, including tumor cells, potentially
produce chemokines and/or express chemokine receptors
(Coussens and Werb 2002; Vicari and Caux 2002).
Chemokines are subgrouped into CC, CXC, C, and CX3C
depending on the spacing or the presence of four N-terminal
cysteine residues (Janeway et al 2001). CXC chemokines
are known to possess pro- or antiangiogenic activities
(Strieter et al 2004).
CXC chemokines with glutamic acid-leucine-arginine
(Glu-Leu-Arg [ELR]) motif (ELR
+), such as interleukin-8
(IL-8), neutrophil-activating protein-2 (NAP-2), granulocyte
chemotactic protein-2 (GCP-2), epithelial-derived
neutrophil-activating protein-78 (ENA-78), growth-related
protein (GRO)-α, -β, and -γ, induce EC migration and
proliferation as potent angiogenic factors (Strieter et al 1995;
Arenberg et al 1998; Vicari and Caux 2002). The receptors
for ELR
+ chemokines are CXCR1 and CXCR2. Limited
members of chemokines such as IL-8 and GCP-2 bind to
CXCR1, whereas all ELR
+ chemokines bind to CXCR2.
Both receptors are inducible on EC surface, and CXCR2 is
regarded as a primary functional receptor for ELR
+
chemokines (Frederick and Clayman 2001).
IFN-γ-inducible CXC chemokines without ELR motif
(ELR
–), such as IFN-inducible T cell α chemoattractant (I-
TAC), monokine induced by IFN-γ (Mig) and IFN-γ-
inducible protein-10 (IP-10), are considered to be
antiangiogenic factors (Frederick and Clayman 2001). These
chemokines share a common receptor, CXCR3, and inhibit
endothelial migration and proliferation (Strieter et al 1995;
Romagnani et al 2001). Another ELR
– chemokine, platelet
factor-4 (PF-4), interferes with EC proliferation and interacts
with CXCR3-B, a variant of CXCR3 (Lasagni et al 2003).
On the other hand, stromal cell derived factor-1 (SDF-1),
one of ELR– CXC chemokines, binds to CXCR4 and
positively induces angiogenesis (Arya et al 2003). CXCR4Vascular Health and Risk Management 2005:1(4) 286
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is expressed abundantly in cultured EC lines (Salcedo et al
2000), and studies on CXCR4–/– mice indicate that SDF-1/
CXCR4 signaling pathway is essential for embryonic blood
vessel formation (Tachibana et al 1998).
Another role of CXC chemokines
that lack Glu-Leu-Arg motif in
tumor progression
Although most of ELR– CXC chemokines are considered
to be antiangiogenic factors, some studies have revealed that
the role of ELR
– chemokines are not limited to anti-
angiogenesis, supported by the fact that CXCR3 is expressed
in a wide variety of cells including tumor cells (Romagnani
et al 1999; Robledo et al 2001; Goldberg-Bittman et al 2004).
It has been demonstrated in in vitro studies that ELR–
chemokines could induce migration of CXCR3
+ tumor cells
such as melanomas and lung carcinomas (Robledo et al
2001; Soejima and Rollins 2001). Furthermore, some CXC
chemokine receptors in tumor cells, eg, CXCR4 in breast
carcinoma cells, are suggested to play key roles in metastasis
of the tumor to particular organs/tissues such as regional
lymph nodes, bone marrow, and lung (Mueller et al 2001;
Helbig et al 2003). Recent studies showed that CXCR3
+
melanoma cells preferentially metastasize to lymph nodes
that highly express Mig and IP-10 (Kawada et al 2004). On
the other hand, in studies on CXCR3
+ neuroblastomas,
administration of ELR– chemokines did not resulted in
increased cell migration or proliferation (Goldberg-Bittman
et al 2005). These results indicate that interaction of ELR
–
chemokines with CXCR3 may potentially work for tumor
progression in some, if not all, CXCR3
+ tumors. It should
be further investigated as to whether immune therapies such
as IL-12 and IFN-γ administration, originally expected to
elicit antiangiogenic effects of ELR
– chemokines (Bukowski
et al 1999; Portielje et al 2003), can be safely applied to
CXCR3
+ tumors or actually lead to tumor progression.
Conclusions and future prospects
The results of preclinical studies using antiangiogenic agents
have warranted the importance of vascular targeting for
better outcomes in human cancer therapies, although the
results vary among the cases (Sivakumar et al 2004).
Prospective antiangiogenic therapies, combined with
conventional chemotherapy and other strategies including
immune- and gene-therapies, may provide successful
approaches for treatment of malignant tumors. Even if
complete eradication cannot be achieved, such combined
therapies may well keep tumors in a state of dormancy.
Further investigation on pathophysiology of neovascular-
ization in the entire course of tumor progression will help
us to improve antiangiogenic approaches against various
types and stages of human malignancies.
Besides tumor vasculature, angiogenesis plays crucial
roles in many other pathological conditions, eg, rheumatoid
arthritis, diabetic retinopathy, and myocardial infarction.
Characteristic features of the vasculature in each condition
may be explained at least in part by the disease-specific
background, such as chronic inflammation, disrupted matrix
remodeling, malfunctioned immunity, and tissue hypoxia.
It is necessary to control both angiogenic factors and tissue
environments that support vessel remodeling for better
management of these pathological conditions. If the
mechanism of pathophysiological neovascularization in
various diseases, including tumors, is fully elucidated, it
will certainly provide more precise disease- and tissue-
specific strategies, and contribute to more effective and safer
therapies in future.
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